Home For Patients About Us Our Physicians Services Specialty Clinics Clinical Studies Contact Us
BLIMC Studies
Title:Predicting pathological response within the first week of neoadjuvant chemotherapy using functional parameters measured with Diffuse Optical Spectroscopy imaging
PI:Bruce Tromberg, Ph.D
ClinicalTrials.gov Registry


The purpose of this study is to determine if Diffuse Optical Spectroscopic Imaging (DOSI) can provide metabolic and functional information that predict tumor response to preoperative (neoadjuvant) chemotherapy in breast cancer patients early (< 1 week) into their treatment. Early, non-invasive indications of tumor response could provide physicians with the information necessary to make evidence-based changes in treatment strategies. In the future, patients who do not demonstrate early signs of response would be spared unnecessary side-effects of ineffective chemotherapy regimen, and could be switched to more effective treatments.


Inclusion requirements:
(1) Female, not pregnant, not breastfeeding
(2) Older than 21 years of age but less than 75 years of age
(3) Will be receiving neoadjuvant chemotherapy for breast cancer

Time Commitment

Optional measurement during first chemotherapy infusion (~4 hours)
Daily DOSI measurements during first week of chemotherapy, up to 7 days (1-2 hr each day)


Total compensation for participation in the entire study is $450. You will be reimbursed for any additional travel costs associated with this study, with a maximum of 9 visits. If you decide to withdraw from the study or are withdrawn by the research team, you will receive compensation for the visits and/or procedures that you have completed.


For more information on participating in this trial, please contact Montana Compton at (949) 824 - 9265 or via email at mocomton@uci.edu

For more information on our clinical studies, click here.

Human Subjects


Ata Sharif